Cargando…

Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK

The pathogenesis of age-related macular degeneration (AMD) is unclear, but it can take either a neovascular/exudative/wet form, characterized by choroidal neovascularization (CNV), or a dry form. No treatments are available for the dry form, but there are a number of pharmacological interventions th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sivaprasad, Sobha, Acharya, Nachiketa, Hykin, Phil
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2008
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693996/ https://www.ncbi.nlm.nih.gov/pubmed/19668726

Ejemplares similares

Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration
por: Sivaprasad, Sobha
Publicado: (2008)

Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany
por: Feucht, Nikolaus, et al.
Publicado: (2008)

Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study
por: Friberg, Thomas R, et al.
Publicado: (2010)

Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration
por: Gohil, Rishma, et al.
Publicado: (2015)

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin, Philip, et al.
Publicado: (2016)

Pegaptanib in the treatment of wet, age-related macular degeneration
por: Vinores, Stanley A
Publicado: (2006)

Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting
por: Gohil, Rishma, et al.
Publicado: (2016)

An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema
por: Sivaprasad, Sobha, et al.
Publicado: (2014)

Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration
por: Chandra, Shruti, et al.
Publicado: (2020)

Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema
por: Querques, G., et al.
Publicado: (2009)

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial
por: Singerman, L J, et al.
Publicado: (2008)

Quantitative Autofluorescence in Non-Neovascular Age Related Macular Degeneration
por: Chandra, Shruti, et al.
Publicado: (2023)

Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting
por: Eleftheriadou, Maria, et al.
Publicado: (2018)

Clinical experience with pegaptanib sodium
por: Rosina, Chiara, et al.
Publicado: (2008)

Visual outcome of ranibizumab therapy for neovascular age related macular degeneration in the black population: a report of five cases
por: Vemala, Roopa, et al.
Publicado: (2010)

Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study
por: Holz, Frank G, et al.
Publicado: (2016)

Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review
por: Hanson, Rachel L. W., et al.
Publicado: (2022)

Effect of Switching Therapy to Pegaptanib in Eyes With the Persistent Cases of Exudative Age-Related Macular Degeneration
por: Shiragami, Chieko, et al.
Publicado: (2014)

Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients with Unilateral Neovascular Age-Related Macular Degeneration: Early Detection of Neovascular Age-Related Macular Degeneration Study
por: Sivaprasad, Sobha, et al.
Publicado: (2021)

A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus
por: Dombi, Theresa, et al.
Publicado: (2012)

Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
por: Nishimura, Yoshihiro, et al.
Publicado: (2012)

Population pharmacokinetics of pegaptanib sodium (Macugen(®)) in patients with diabetic macular edema
por: Basile, Anthony S, et al.
Publicado: (2015)

Newly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review study
por: Weber, Pamela A, et al.
Publicado: (2010)

Monitoring for neovascular age-related macular degeneration (AMD) reactivation at home: the MONARCH study
por: Ward, Elizabeth, et al.
Publicado: (2020)

Pegaptanib sodium for ocular vascular disease
por: Shukla, Dhananjay, et al.
Publicado: (2007)

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
por: Holz, Frank G, et al.
Publicado: (2015)

Scotopic thresholds on dark-adapted chromatic perimetry in healthy aging and age-related macular degeneration
por: Grewal, Manjot Kaur, et al.
Publicado: (2021)

Health-related quality of life, visual function and treatment satisfaction following intravitreal dexamethasone implant for diabetic macular edema
por: Ramu, Jayashree, et al.
Publicado: (2017)

Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema
por: Kiire, Christine A, et al.
Publicado: (2015)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

An exploratory study evaluating the effects of macular carotenoid supplementation in various retinal diseases
por: Crosby-Nwaobi, Roxanne, et al.
Publicado: (2016)

Patient Acceptability of Home Monitoring for Neovascular Age-Related Macular Degeneration Reactivation: A Qualitative Study
por: O’Connor, Seán R., et al.
Publicado: (2022)

The MATE trial: a multicentre, mixed-methodology, pilot, randomised controlled trial in neovascular age-related macular degeneration
por: Airody, Archana, et al.
Publicado: (2023)

Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes
por: Mathis, Thibaud, et al.
Publicado: (2022)

Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration
por: Talks, J S, et al.
Publicado: (2017)

Radiation therapy for neovascular age-related macular degeneration
por: Petrarca, Robert, et al.
Publicado: (2011)

Experimental Models in Neovascular Age Related Macular Degeneration
por: Rastoin, Olivia, et al.
Publicado: (2020)

Pipeline therapies for neovascular age related macular degeneration
por: Arepalli, Sruthi, et al.
Publicado: (2021)

Association of neovascular age-related macular degeneration with migraine
por: Kuang, Tung-Mei, et al.
Publicado: (2022)

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
por: Rotsos, Tryfon, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_trobcjtc0ra648petqhgo7pbdf